Trial
NCT04973137
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Prothena Biosciences Ltd.
Collaborators
—
Condition
Light Chain (AL) Amyloidosis
Intervention
Birtamimab
Why stopped
The AFFIRM-AL clinical trial did not meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-16